E. Dühmke

home / authors / e-dühmke

Articles

Site Logo

2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany

H. Tesch;M. Sieber;J. U. Rüffer;J. Franklin;R. Herrmann;F. Boissevain;A. Franke;M. Pfreundschuh;D. Hossfeld;E. Dühmke;J. Wolf;A. Engert;U. Paulus;V. Diehl
March 1st 1999

BACKGROUND: Extended-field radiotherapy is effective in patients with early-stage Hodgkin’s disease, and more than

Site Logo

Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease

V. Diehl;J. Franklin;M. Sieber;D. Hasenclever;U. Paulus;H. Tesch;M. Pfreundschuh;U. Rüffer;R. Hermann;C. Longin;M. Hänel;G. Wulf;W. Aulitzky;A. Georgii;E. Dühmke;M. Loeffler
March 1st 1999

This report aims to assess the effect of increased drug dose on the efficacy and toxicity of the BEACOPP regimen with

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: July 6th 2025
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes